152 related articles for article (PubMed ID: 15977912)
1. Costs associated with the management of overactive bladder and related comorbidities.
Darkow T; Fontes CL; Williamson TE
Pharmacotherapy; 2005 Apr; 25(4):511-9. PubMed ID: 15977912
[TBL] [Abstract][Full Text] [Related]
2. Health Resource Utilization and Cost for Patients with Incontinent Overactive Bladder Treated with Anticholinergics.
Yehoshua A; Chancellor M; Vasavada S; Malone DC; Armstrong EP; Joshi M; Campbell K; Pulicharam R
J Manag Care Spec Pharm; 2016 Apr; 22(4):406-13. PubMed ID: 27023694
[TBL] [Abstract][Full Text] [Related]
3. The economic burden of overactive bladder (OAB) and its effects on the costs associated with other chronic, age-related comorbidities in the United States.
Durden E; Walker D; Gray S; Fowler R; Juneau P; Gooch K
Neurourol Urodyn; 2018 Jun; 37(5):1641-1649. PubMed ID: 29464813
[TBL] [Abstract][Full Text] [Related]
4. Clinical Burden and Nonpharmacologic Management of Nursing Facility Residents with Overactive Bladder and/or Urinary Incontinence.
Zarowitz BJ; Allen C; O'Shea T; Tangalos E; Berner T; Ouslander JG
Consult Pharm; 2015 Sep; 30(9):533-42. PubMed ID: 26350894
[TBL] [Abstract][Full Text] [Related]
5. Health-related consequences of overactive bladder.
Wagner TH; Hu TW; Bentkover J; LeBlanc K; Stewart W; Corey R; Zhou Z; Hunt T
Am J Manag Care; 2002 Dec; 8(19 Suppl):S598-607. PubMed ID: 12516954
[TBL] [Abstract][Full Text] [Related]
6. Association between overactive bladder treatment and falls among older adults.
Jayadevappa R; Chhatre S; Newman DK; Schwartz JS; Wein AJ
Neurourol Urodyn; 2018 Nov; 37(8):2688-2694. PubMed ID: 29806158
[TBL] [Abstract][Full Text] [Related]
7. Primary Nonadherence to Overactive Bladder Medications in an Integrated Managed Care Health Care System.
Rashid N; Vassilakis M; Lin KJ; Kristy R; Ng DB
J Manag Care Spec Pharm; 2017 Apr; 23(4):484-493. PubMed ID: 28345439
[TBL] [Abstract][Full Text] [Related]
8. Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin.
Jumadilova Z; Varadharajan S; Girase P; Ollendorf DA
Am J Health Syst Pharm; 2006 Dec; 63(23):2357-64. PubMed ID: 17106009
[TBL] [Abstract][Full Text] [Related]
9. Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United States.
Qin L; Luo X; Zou KH; Snedecor SJ
J Med Econ; 2016; 19(3):229-35. PubMed ID: 26488196
[TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder.
Pelletier EM; Vats V; Clemens JQ
Am J Manag Care; 2009 Mar; 15(4 Suppl):S108-14. PubMed ID: 19355799
[TBL] [Abstract][Full Text] [Related]
11. Increased Healthcare Resource Utilization and Direct and Indirect Costs in Patients with Depression and Comorbid Overactive Bladder: Evidence From a Retrospective, Matched Case-Control Cohort Analysis.
Shiozawa A; Hopson S; Fuldeore R; Stoelzel M; Ng D; Hairston J
Adv Ther; 2020 Nov; 37(11):4599-4613. PubMed ID: 32910419
[TBL] [Abstract][Full Text] [Related]
12. Costs and resources associated with the treatment of overactive bladder using retrospective medical care claims data.
Hall JA; Nelson MA; Meyer JW; Williamson T; Wagner S
Manag Care Interface; 2001 Aug; 14(8):69-75. PubMed ID: 11517841
[TBL] [Abstract][Full Text] [Related]
13. Estimated economic costs of overactive bladder in the United States.
Hu TW; Wagner TH; Bentkover JD; LeBlanc K; Piancentini A; Stewart WF; Corey R; Zhou SZ; Hunt TL
Urology; 2003 Jun; 61(6):1123-8. PubMed ID: 12809878
[TBL] [Abstract][Full Text] [Related]
14. Impact of coexisting overactive bladder in Medicare patients with osteoporosis.
Caplan EO; Abbass IM; Suehs BT; Ng DB; Gooch K; Kirby C; Abbott P
Arch Gerontol Geriatr; 2018; 75():44-50. PubMed ID: 29180131
[TBL] [Abstract][Full Text] [Related]
15. The economic impact of overactive bladder syndrome in six Western countries.
Irwin DE; Mungapen L; Milsom I; Kopp Z; Reeves P; Kelleher C
BJU Int; 2009 Jan; 103(2):202-9. PubMed ID: 19278532
[TBL] [Abstract][Full Text] [Related]
16. Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study.
Szabo SM; Gooch K; Schermer C; Walker D; Lozano-Ortega G; Rogula B; Deighton A; Vonesh E; Campbell N
BMJ Open; 2019 May; 9(5):e026391. PubMed ID: 31061036
[TBL] [Abstract][Full Text] [Related]
17. The economic costs of overactive bladder in Germany.
Klotz T; Brüggenjürgen B; Burkart M; Resch A
Eur Urol; 2007 Jun; 51(6):1654-62; discussion 1662-3. PubMed ID: 17161521
[TBL] [Abstract][Full Text] [Related]
18. The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.
Ng DB; Espinosa R; Johnson SJ; Walker D; Gooch K
J Med Econ; 2017 Dec; 20(12):1272-1280. PubMed ID: 28805473
[TBL] [Abstract][Full Text] [Related]
19. Impact of Coexisting Overactive Bladder in Medicare Patients With Dementia on Clinical and Economic Outcomes.
Caplan EO; Abbass IM; Suehs BT; Ng DB; Gooch K; van Amerongen D
Am J Alzheimers Dis Other Demen; 2019; 34(7-8):492-499. PubMed ID: 30966757
[TBL] [Abstract][Full Text] [Related]
20. Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder.
Tang DH; Colayco DC; Khalaf KM; Piercy J; Patel V; Globe D; Ginsberg D
BJU Int; 2014 Mar; 113(3):484-91. PubMed ID: 24528881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
